<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(4)</volume><submitter>Rafiei A</submitter><pubmed_abstract>The hallmark of Philadelphia chromosome positive (Ph(+)) leukemia is the BCR/ABL kinase, which is successfully targeted by selective ATP competitors. However, inhibition of BCR/ABL alone is unable to eradicate Ph(+) leukemia. The t(9;22) is a reciprocal translocation which encodes not only for the der22 (Philadelphia chromosome) related BCR/ABL, but also for der9 related ABL/BCR fusion proteins, which can be detected in 65% of patients with chronic myeloid leukemia (CML) and 100% of patients with Ph+ acute lymphatic leukemia (ALL). ABL/BCRs are oncogenes able to influence the lineage commitment of hematopoietic progenitors. Aim of this study was to further disclose the role of p96(ABL/BCR) for the pathogenesis of Ph(+) ALL. The co-expression of p96(ABL/BCR) enhanced the kinase activity and</pubmed_abstract><journal>PLoS genetics</journal><pagination>e1005144</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4412790</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.</pubmed_title><pmcid>PMC4412790</pmcid><pubmed_authors>Mian AA</pubmed_authors><pubmed_authors>Metodieva A</pubmed_authors><pubmed_authors>Rafiei A</pubmed_authors><pubmed_authors>Oancea C</pubmed_authors><pubmed_authors>Ottmann OG</pubmed_authors><pubmed_authors>Doring C</pubmed_authors><pubmed_authors>Ruthardt M</pubmed_authors><pubmed_authors>Thalheimer FB</pubmed_authors><pubmed_authors>Hansmann ML</pubmed_authors></additional><is_claimable>false</is_claimable><name>The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.</name><description>The hallmark of Philadelphia chromosome positive (Ph(+)) leukemia is the BCR/ABL kinase, which is successfully targeted by selective ATP competitors. However, inhibition of BCR/ABL alone is unable to eradicate Ph(+) leukemia. The t(9;22) is a reciprocal translocation which encodes not only for the der22 (Philadelphia chromosome) related BCR/ABL, but also for der9 related ABL/BCR fusion proteins, which can be detected in 65% of patients with chronic myeloid leukemia (CML) and 100% of patients with Ph+ acute lymphatic leukemia (ALL). ABL/BCRs are oncogenes able to influence the lineage commitment of hematopoietic progenitors. Aim of this study was to further disclose the role of p96(ABL/BCR) for the pathogenesis of Ph(+) ALL. The co-expression of p96(ABL/BCR) enhanced the kinase activity and</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Apr</publication><modification>2025-04-04T23:23:58.399Z</modification><creation>2019-03-26T22:42:14Z</creation></dates><accession>S-EPMC4412790</accession><cross_references><pubmed>25919613</pubmed><doi>10.1371/journal.pgen.1005144</doi></cross_references></HashMap>